Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.5% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health, Inc. (NASDAQ: HIMS) is a digital health company that offers personalized telehealth services and prescription medication delivery.

Why is Hims & Hers Health Inc. going down?

HIMS stock is down 5.5% on Apr 8, 2026 20:01

• The CFO's sale of shares and exercising of options may have signaled a lack of confidence in the company's future prospects, contributing to the bearish movement.
• The investigation initiated by a legal firm, and the investor lawsuit over alleged misconduct have likely raised concerns among investors, leading to a negative sentiment towards the stock.
• The termination of the partnership with another company and the allegations of deceptive marketing and failure to adhere to laws regarding compounded drugs have cast a shadow on Hims & Hers Health's reputation, impacting its stock performance negatively.
• The combination of insider selling, legal troubles, and ethical concerns has created a perfect storm of bad news for Hims & Hers Health, resulting in the bearish market movement observed today.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Okupe, Hims & Hers health CFO, sells $79k in shares By Investing.com

Oluyemi Okupe, CFO of Hims & Hers Health, Inc. (NASDAQ:HIMS), recently sold 3,975 Class A Common Stock shares for about $79,408 and simultaneously exercised options to acquire the same number of shares. These transactions were part of a pre-arranged trading plan, and Okupe continues to hold a significant number of shares. This insider activity comes as Hims & Hers Health announced a partnership with Novo Nordisk to offer GLP-1 medications and is experiencing a notable rally in its stock.

https://m.za.investing.com/news/insider-trading-news/okupe-hims--hers-health-cfo-sells-79k-in-shares-93CH-4200888?ampMode=1

Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS

Kahn Swick & Foti, LLC (KSF) has launched an investigation into Hims & Hers Health, Inc. (HIMS) and its officers and directors following a securities class action lawsuit. This investigation stems from Novo Nordisk terminating its partnership with Hims & Hers, alleging the company failed to adhere to laws regarding mass sales of compounded drugs and disseminated deceptive marketing. A court has denied Hims & Hers' motion to dismiss the lawsuit, allowing the case to proceed.

https://www.businesswire.com/news/home/20260403774577/en/Hims-Hers-Health-Investigation-Initiated-Kahn-Swick-Foti-LLC-Investigates-the-Officers-and-Directors-of-Hims-Hers-Health-Inc.---HIMS

Hims & Hers Health Faces Investor Lawsuit Over Alleged Misconduct

Hims & Hers Health Inc. is facing an investor lawsuit and investigation by Kahn Swick & Foti, LLC, following allegations that the company failed to disclose material information and made misrepresentations about its operations. This legal action stems from Novo Nordisk terminating its partnership with Hims & Hers due to the latter's alleged failure to adhere to laws regarding compounded drugs and deceptive marketing. The ongoing case raises significant concerns about transparency and ethical practices within the digital health industry.

https://nationaltoday.com/us/la/new-orleans/news/2026/04/03/hims-hers-health-faces-investigation-over-alleged-misconduct/

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 6.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.3% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.5% Today

Mohawk Industries Inc. ($MHK) Stock Forecast: Down 5.3% Today

Paycom Software Inc. ($PAYC) Stock Forecast: Down 6.8% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Down 5.6% Today

Salesforce.com Inc ($CRM) Stock Forecast: Down 5.2% Today

Sonos Inc. ($SONO) Stock Forecast: Down 6.6% Today

Reddit Inc ($RDDT) Stock Forecast: Down 5.6% Today

Devon Energy Corporation ($DVN) Stock Forecast: Up 5.8% Today

Hims & Hers Health Inc. Price History

20.02.2026 - HIMS Stock was down 8.2%

• Concerns were raised by a former FDA commissioner regarding the effectiveness of Hims & Hers' proprietary weight-loss drug, which utilizes different technology compared to products from Novo Nordisk.
• Despite a renewed collaboration with Novo Nordisk, investor jitters were likely caused by an investigation into potential securities fraud conducted by the Portnoy Law Firm, contributing to the bearish trend.
• The negative sentiment surrounding HIMS stock was amplified by a substantial sell-off triggered when Novo Nordisk terminated their partnership in weight-loss drug sales.
• In the short term, investor confidence may have been affected by the company's decision to cease sales of compounded GLP-1 drugs and focus on the distribution of branded versions.

18.02.2026 - HIMS Stock was down 5.5%

• An investigation into possible securities fraud concerning Hims & Hers Health, Inc.'s suspension of sales for its branded weight-loss medication was conducted by the Portnoy Law Firm. This likely sparked investor concerns and led to the bearish market activity.
• The termination of a partnership by Novo Nordisk in relation to weight-loss medication sales might have prompted a substantial sell-off, contributing to the overall pessimism surrounding the stock.
• Hims & Hers Health, Inc.'s acquisition of Eucalyptus, an Australian digital health organization, to expand its international presence, could have instilled uncertainty about integration expenses and regulatory requirements, further impacting the stock's performance.
• Despite a recent 57% rise in share price, a reevaluation of the company's worth by investors and considerations about regulatory oversight may have also influenced the negative market trend witnessed today.

07.03.2026 - HIMS Stock was down 5.1%

• HIMS stock displayed a significant downward trend today.
• Concerns among investors have been elevated by an investigation and lawsuit initiated by Kahn Swick & Foti, LLC, surrounding alleged misconduct by Hims & Hers Health, particularly in relation to its termination of partnership with Novo Nordisk.
• The negative market sentiment towards HIMS can be attributed to legal actions and regulatory scrutiny, including accusations of deceptive marketing and non-compliance with laws regarding compounded drugs.
• Despite potential growth prospects stemming from the Novo Nordisk partnership, uncertainties and legal issues faced by Hims & Hers Health have overshadowed the positive developments, leading to the downward movement in the market.

10.02.2026 - HIMS Stock was up 6.1%

• The positive news of the company re-partnering with Novo Nordisk to sell FDA-approved diabetes and obesity treatments led to the dismissal of a patent infringement lawsuit and a significant rise in Hims shares.
• Despite potential near-term margin weakness, the shift from advertising compounded GLP-1 medications to promoting FDA-approved versions likely boosted investor confidence in the company's future prospects.
• Bullish options activity and varied analyst opinions, with a consensus target price of $30.1, reflect optimism and interest in Hims & Hers Health's potential growth trajectory.

02.03.2026 - HIMS Stock was down 7.9%

• The stock of HIMS experienced a significant drop due to potential securities law violations and lawsuits related to the sale of compounded drugs, leading to investor concerns and a bearish sentiment.
• Despite a recent pullback, the company is trading at a discount to its intrinsic value and analyst price targets, indicating a lack of confidence in its future performance.
• The internal realignment by Vanguard, reporting 0 shares beneficially owned, might have added to the negative sentiment surrounding HIMS, signaling a lack of institutional support.
• The regulatory scrutiny and increased competition faced by Hims & Hers Health Inc. could further impact its stock price, highlighting the importance of monitoring price action for tactical trading decisions.

25.02.2026 - HIMS Stock was down 5.5%

• The bearish movement in HIMS stock today might be linked to the insider trading activity of the Chief Financial Officer, Oluyemi Okupe, who recently sold a significant number of shares.
• Recent positive developments, such as a partnership renewal with Novo Nordisk for weight loss drugs and a stock upgrade by a securities firm, have been overshadowed by an ongoing investigation into alleged misrepresentations and securities law violations.
• Despite the company's potential for growth through strategic partnerships, HIMS is currently undervalued according to a recent valuation analysis.
• The launch of a waitlist for FDA-approved weight-loss medications with Novo Nordisk is seen as a positive step, but it may not have been sufficient to counteract the negative impact of insider trading and legal scrutiny, leading to today's bearish market movement for HIMS.

08.03.2026 - HIMS Stock was down 5.5%

• The CFO's sale of shares and exercising of options may have signaled a lack of confidence in the company's future prospects, contributing to the bearish movement.
• The investigation initiated by a legal firm, and the investor lawsuit over alleged misconduct have likely raised concerns among investors, leading to a negative sentiment towards the stock.
• The termination of the partnership with another company and the allegations of deceptive marketing and failure to adhere to laws regarding compounded drugs have cast a shadow on Hims & Hers Health's reputation, impacting its stock performance negatively.
• The combination of insider selling, legal troubles, and ethical concerns has created a perfect storm of bad news for Hims & Hers Health, resulting in the bearish market movement observed today.

31.02.2026 - HIMS Stock was up 5.8%

• Despite recent challenges and regulatory scrutiny, Hims & Hers Health Inc. (HIMS) experienced a bullish movement with its stock today.
• The company's valuation, currently trading at a discount to its intrinsic value, is backed by fast revenue growth and increasing profitability.
• A prior investigation into potential securities law violations by a legal firm and FDA restrictions caused a significant stock pullback.
• Today's bullish sentiment may stem from renewed investor confidence in the company's long-term growth prospects and strategic actions to address regulatory concerns.

24.02.2026 - HIMS Stock was down 5.3%

• The renewal of the partnership with Novo Nordisk for weight loss drugs showcased growth potential. However, questions about the legality and safety of Hims & Hers compounded drugs post-partnership termination caused investor worry.
• An investigation by Kahn Swick & Foti, LLC into alleged misrepresentations and securities law violations by Hims & Hers Health's officers and directors added further doubt, impacting the market negatively.
• Despite the introduction of a waitlist for FDA-approved weight-loss medications with Novo Nordisk, concerns about legal issues and valuation likely influenced the stock's performance.
• Insider selling of shares by Hims & Hers Health's Chief Legal Officer through a pre-arranged trading plan may have also affected investor confidence, indicating potential internal issues within the company.

12.02.2026 - HIMS Stock was down 7.1%

• The end of a partnership with Novo Nordisk, a securities class action lawsuit, and accusations of violating laws related to mass sales of compounded drugs and deceptive marketing are believed to have influenced the decline in HIMS stock.
• Although HIMS resolved the partnership issue with Novo Nordisk to provide branded obesity drugs, ongoing uncertainties and potential near-term margin challenges, as pointed out by Morningstar, may have impacted investor confidence.
• Real-time signal analysis suggesting increased downside risk and Novo Nordisk's decision to sell its weight-loss drug through the telehealth platform might have contributed to the negative market sentiment surrounding HIMS.
• Investors could be reacting to the changes in supply and regulatory requirements resulting from the shift to branded therapies from compounded alternatives, affecting Hims & Hers Health's investment outlook and possibly raising concerns about its future performance.

27.02.2026 - HIMS Stock was down 5.1%

• Today's bearish movement in HIMS stock may be linked to an ongoing investigation into potential securities law violations related to compounded GLP-1 active pharmaceutical ingredients by the Schall Law Firm, and a lawsuit from Novo Nordisk concerning the sale of compounded weight loss drugs.
• The CFO of Hims & Hers Health, Oluyemi Okupe, engaged in insider trading by selling a substantial amount of shares, possibly contributing to the negative market sentiment.
• Despite recent positive developments such as partnerships and the renewal of the weight loss drug partnership with Novo Nordisk, analysts have noted concerns about the stock's valuation, suggesting it may be undervalued compared to its current price. This perceived disparity could be a factor fueling the sell-off in the stock.

11.02.2026 - HIMS Stock was up 5.9%

• The bullish movement in HIMS stock can be attributed to the positive news of the re-partnership between Hims & Hers and Novo Nordisk to sell FDA-approved diabetes and obesity treatments. This move not only resolves the legal overhang from the patent infringement lawsuit but also opens up new revenue streams for HIMS.
• The settlement of the legal dispute and the agreement to sell Novo Nordisk's weight-loss drug on the telehealth platform indicates a strategic shift for both companies, which has likely boosted investor confidence in the potential growth prospects for HIMS.
• The real-time signal analysis highlighting a strong sentiment in the near term and the elevated downside risk due to a lack of long-term support signals may have also contributed to increased trading activity and buying interest in HIMS stock.